The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve. In prior studies, tubal ligation has been shown to have an adverse effect on ovarian reserve. One theory postulated for this effect is that the ovarian circulation is disrupted by the procedure, leading to altered hormone production. In this prospective cohort study, the investigators plan to analyze the rates of AMH decline by comparing the following contraceptive methods: tubal ligation, Essure placement, and levonorgestrel intrauterine devices (IUDs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing Ovarian Function During Prolonged Implant Use

NCT03058978

Contraception

COMPLETED

Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception

NCT02785809

Oral Contraceptives Long-term Use AMH +1 more

UNKNOWN

Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders

NCT03826888

Anti-Mullerian Hormone Isoforms

COMPLETED

Patient Compliance With Long-Acting Reversible Contraception Administration

NCT03305081

Contraception

TERMINATED NA

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186

Hemostasis Oral Contraceptive

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve because levels demonstrate a consistent age-related decline and do not fluctuate throughout the menstrual cycle. In prior studies measuring markers other than AMH, tubal ligation has been shown to have an adverse effect on ovarian reserve.

The primary aim of this study will be to compare the rates of anti-mullerian hormone (AMH) decline following tubal ligation, Essure placement, and levonorgestrel IUDs, and then identifying any and all differences that these specific contraceptive methods have on the changes of AMH rates over time. The secondary aim will focus on analyzing the various types of tubal ligation methods (i.e. coagulation, ligation, clips, bands, etc.) to see if different techniques result in any difference in the rate of AMH decline. The hypothesis is that tubal ligation will result in an accelerated rate of AMH decline as compared to other long-term or permanent contraceptive methods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Birth Control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tubal ligation

Patients who elect to have tubal ligation

No interventions assigned to this group

Essure

Group that elects to have Essure placement

No interventions assigned to this group

Levonorgestrel IUD

Patients that elect to have a levonorgestrel intra-uterine device placement

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* English-speaking
* Female
* Age 25-40
* Electing one of the following contraceptive methods: tubal ligation, Essure, levonorgestrel IUD
* Ability to understand study procedures and to comply with them for the entire length of the study
* Willingness to comply with follow-up visit requirements

Exclusion Criteria

* Age \<25 or \>40 at initiation or completion of the study
* Prior oophorectomy or salpingectomy
* Prior surgery of the ovaries or fallopian tubes
* Prior ovarian, uterine, or fallopian tube cancers
* Prior ovarian, uterine, or fallopian tube radiation exceeding \>200rads
* Prior platinum-based or alkalizing chemotherapy
* Current cancer (any form)
* Current pregnancy
* Allergy to any of the components of the selected devices (titanium, rubber, nickel, plastic, silicone)
* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
* Inability or unwillingness of a potential participant to give written informed consent
* Inability for the potential participant to consent for herself

Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No